First-in-Kind AI-Powered Whole-Body Imaging for Precision Medicine

Cel

The high failure rate of drug candidates in late-stage development poses a significant challenge to the pharmaceutical industry. This is primarily attributed to unforeseen toxicity, off-target effects, and lack of efficacy.
Current imaging techniques, such as MRI and PET, lack the resolution to provide a comprehensive, single cell view of therapeutic distribution within an organism. This limitation is particularly crucial for advanced therapies like mRNA-based drugs, gene therapies, and nanocarriers, which necessitate precise cellular targeting. The inability to track these therapies in sufficient detail results in late-stage failures, increased costs, and greater reliance on animal testing.
Deep Piction’s mission is to transform targeted therapeutic development by providing unparalleled cell-level insights into drug distribution, targeting, and efficacy through our proprietary AI-driven whole-body cellular imaging technology.
As the only company offering this level of spatial and molecular detail, we empower biopharmaceutical companies to optimise therapeutic molecules with unmatched precision - reducing off-target toxicity and enhancing treatment efficacy.
Deep Piction is unique: zero-slicing, entire-organism coverage, single-cell detail, plus optional mRNA/protein labeling. Our robust patent portfolio - transferred from our academic roots - protects the unique chemistry, optics, and computational methods that power our breakthrough.
By bridging the gap between preclinical research and clinical success, we drive the development of safer, more effective drugs and expand the potential for next-generation therapies through precise cell- level targeting.
With the EIC funding, we will finalise the standardisation of mRNA labeling in entire adult mouse bodies, scale our commercial efforts, and remain the only solution offering such transformative 3D subcellular analysis.